Cas:887591-20-0 tert-butyl 4-(2-bromophenyl)sulfonylpiperidine-1-carboxylate manufacturer & supplier

Chemical Name:tert-butyl 4-(2-bromophenyl)sulfonylpiperidine-1-carboxylate

CAS.NO:887591-20-0

Synonyms:4-(2-BROMO-BENZENESULFONYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;tert-butyl 4-(2-bromophenylsulfonyl)piperidine-1-carboxylate;1-Piperidinecarboxylicacid,4-[(2-bromophenyl)sulfonyl]-,1,1-dimethylethyl ester;QC-7839

Molecular Formula:C₁₆H₂₂BrNO₄S

Molecular Weight:404.31900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:72.06000

Exact Mass:403.04500

LogP:4.64100

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-(2-BROMO-BENZENESULFONYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,QC-7839 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(2-BROMO-BENZENESULFONYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER Use and application,4-(2-BROMO-BENZENESULFONYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER technical grade,usp/ep/jp grade.

Related News: In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. tert-butyl 4-(2-bromophenyl)sulfonylpiperidine-1-carboxylate manufacturer In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. tert-butyl 4-(2-bromophenyl)sulfonylpiperidine-1-carboxylate supplier It also said it would bar South Koreans from visiting China as tourists. tert-butyl 4-(2-bromophenyl)sulfonylpiperidine-1-carboxylate vendor China has granted conditional approval to its first self-developed treatment for Alzheimer��s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug. tert-butyl 4-(2-bromophenyl)sulfonylpiperidine-1-carboxylate factory China has granted conditional approval to its first self-developed treatment for Alzheimer��s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.